MX9804119A - Analogos de antraciclina citotoxica dirigidos. - Google Patents
Analogos de antraciclina citotoxica dirigidos.Info
- Publication number
- MX9804119A MX9804119A MX9804119A MX9804119A MX9804119A MX 9804119 A MX9804119 A MX 9804119A MX 9804119 A MX9804119 A MX 9804119A MX 9804119 A MX9804119 A MX 9804119A MX 9804119 A MX9804119 A MX 9804119A
- Authority
- MX
- Mexico
- Prior art keywords
- deamino
- doxorubicin
- dox
- analogs
- moiety
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invencion se encuentra en el campo de la química de dirigir derivados de antraciclina anticancerosos, Más en particular, se relaciona con la doxorrubicina (DOX) o con sus derivados modificados de daunosamina (DM-DOX) ligados covalentemente a análogos de hormonas de péptidos, tales como LR-HR, bombesina y somatostatina. Estos conjugados covalentes se dirigen a varios tumores portadores de receptores para los análogos de hormonas de péptidos. Los compuestos de esta invencion están representados por la formula general: Q14-O-R-P, en la cual Q tiene la formula general (II), donde: Q14 significa una parte Q con una cadena lateral en la posicion 14; R- es H o -C(O)- (CH2)n-C(O)-y n = 0-7; R' es NH2 o un compuesto heterocíclico de 5 o 6 miembros, saturado o parcialmente saturado, aromático, que tiene por lo menos un nitrogeno de cadena cerrada y, opcionalmente, que tiene una parte de butadieno ligada a átomos de carbono adyacentes de dicha cadena cerrada para formar un sistema bicíclico; P es H o una parte de péptido, convenientemente un análogo de LHRH, somatostatina o bombesina. Sin embargo, cuando R y P son H, entonces R' debe ser distinta de NH2. Se ha descubierto una nueva reaccion sintética en el curso de este trabajo para formar partes heterocíclicas parcialmente saturadas a partir de aminas vicinales y disyuntivas, es decir alfa, beta- o alfa, y-hidroxi primarias. Q1 es DOX; Q2 es 3'-deamino-3'-(pirrolidin-1"-il)-doxorrubicina (AN 181); Q3 es 3'-deamino-3'-(isoindolin-1"-il)-doxorrubicina (AN 184); Q4 es 3'-deamino-3'-(32-pirrolin-1"-il)-doxorrubicina (AN 185): Q5 es 3'-deamino-3'-(3"-pirrolidon-1"-il)-doxorrubicina (AN 191); Q6 es 3'-deamino-3'(2"-pirrolin-1"-il)-doxorrubicina (AN 201); Q7 es 3'-deamino-3'-(3"-piperidon-1"-il)-doxorrubicina (AN 195); Q8 es 3'-deamino-3'-(1"-3"-tetrahidropiridin-1"-il)-doxo rrubicina (AN 205). Q114gL es AN 152; Q614gL es AN 207; Q114gS es AN 162; Q614gS es AN 238; Q114gB es AN 160; Q614gB es AN 215.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/562,652 US5843903A (en) | 1995-11-27 | 1995-11-27 | Targeted cytotoxic anthracycline analogs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX9804119A true MX9804119A (es) | 1998-09-30 |
Family
ID=24247176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX9804119A MX9804119A (es) | 1995-11-27 | 1998-05-25 | Analogos de antraciclina citotoxica dirigidos. |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US5843903A (es) |
| EP (2) | EP0863917B1 (es) |
| JP (2) | JP3987575B2 (es) |
| KR (2) | KR100467899B1 (es) |
| CN (2) | CN1137136C (es) |
| AT (2) | ATE251179T1 (es) |
| AU (1) | AU709539B2 (es) |
| BR (1) | BR9611647B1 (es) |
| CA (2) | CA2238574C (es) |
| CZ (1) | CZ297297B6 (es) |
| DE (2) | DE69630233T2 (es) |
| DK (2) | DK1384710T3 (es) |
| EA (1) | EA001372B1 (es) |
| ES (2) | ES2205067T3 (es) |
| HK (2) | HK1017363A1 (es) |
| HU (1) | HU229870B1 (es) |
| IL (3) | IL119691A (es) |
| IS (2) | IS2178B (es) |
| MX (1) | MX9804119A (es) |
| NO (2) | NO324035B1 (es) |
| NZ (1) | NZ322054A (es) |
| PL (3) | PL187230B1 (es) |
| PT (2) | PT1384710E (es) |
| SK (2) | SK284672B6 (es) |
| UA (1) | UA67722C2 (es) |
| WO (1) | WO1997019954A1 (es) |
| ZA (1) | ZA969709B (es) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6576239B1 (en) | 1996-09-10 | 2003-06-10 | The Burnham Institute | Angiogenic homing molecules and conjugates derived therefrom |
| US6180084B1 (en) | 1998-08-25 | 2001-01-30 | The Burnham Institute | NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same |
| GB9814527D0 (en) * | 1998-07-03 | 1998-09-02 | Cyclacel Ltd | Delivery system |
| EP1958961A3 (en) | 1998-11-13 | 2008-09-03 | Cyclacel Limited | Transport Vectors |
| FR2786398B1 (fr) * | 1998-11-30 | 2002-12-27 | Synt Em | Composition pharmaceutique anti-cancereuse et anti-chimioresistance comprenant un agent anticancereux et au moins un peptide |
| FR2786397B1 (fr) * | 1998-11-30 | 2003-01-10 | Synt Em | Vecteurs peptidiques de substances a travers la barriere hematoencephalique pour etre utilises dans le diagnostic ou la therapie d'une affection du snc |
| US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| US6528481B1 (en) | 1999-02-16 | 2003-03-04 | The Burnam Institute | NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods |
| US6380161B1 (en) | 1999-06-21 | 2002-04-30 | Inkine Pharmaceutical Company, Inc. | Compositions for treating chemotherapy-resistant tumor cells and targeted chemotherapy compositions |
| EP1235598A2 (en) * | 1999-11-12 | 2002-09-04 | Angiotech Pharmaceuticals, Inc. | Compositions of a combination of radioactive therapy and cell-cycle inhibitors |
| DE60031793T2 (de) | 1999-12-29 | 2007-08-23 | Immunogen Inc., Cambridge | Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung |
| AU4267700A (en) * | 2000-01-13 | 2001-07-19 | Academia Sinica | Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells |
| IL152466A0 (en) * | 2000-04-26 | 2003-05-29 | Mallinckrodt Inc | RgD (Arg-Gly-Asp) COUPLED TO (NEURO) PEPTIDES |
| US7452964B2 (en) | 2001-09-07 | 2008-11-18 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides against placenta and adipose tissues |
| US20040170955A1 (en) | 2000-09-08 | 2004-09-02 | Wadih Arap | Human and mouse targeting peptides identified by phage display |
| US7420030B2 (en) | 2000-09-08 | 2008-09-02 | The Board Of Regents Of The University Of Texas System | Aminopeptidase A (APA) targeting peptides for the treatment of cancer |
| KR100420007B1 (ko) * | 2001-04-25 | 2004-03-02 | 노영쇠 | 안트라사이클린 유도체 및 이를 포함하는 항암제 |
| MXPA04002621A (es) | 2001-09-21 | 2004-07-08 | Univ Tulane | Conjugados de analogos de somatostatina o bombesina para diagnostico o terapeuticos y usos de los mismos. |
| WO2003072754A2 (en) * | 2002-02-27 | 2003-09-04 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use |
| DE60331049D1 (de) | 2002-03-01 | 2010-03-11 | Univ Tulane | Konjugate von zytotoxischen mitteln und biologisch aktiven peptiden |
| US7544767B2 (en) | 2002-04-05 | 2009-06-09 | Burnham Institute For Medical Research | HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells |
| BR0306685A (pt) * | 2002-05-21 | 2005-04-26 | Daiichi Suntory Pharma Co Ltd | Composição farmacêutica contendo grelina |
| CN100341589C (zh) | 2002-05-24 | 2007-10-10 | 血管技术国际股份公司 | 用于涂覆医用植入物的组合物和方法 |
| US8313760B2 (en) | 2002-05-24 | 2012-11-20 | Angiotech International Ag | Compositions and methods for coating medical implants |
| CA2633589A1 (en) | 2002-09-26 | 2004-04-08 | Angiotech International Ag | Perivascular wraps |
| JP2006516548A (ja) | 2002-12-30 | 2006-07-06 | アンジオテック インターナショナル アクツィエン ゲゼルシャフト | 迅速ゲル化ポリマー組成物からの薬物送達法 |
| US20040202666A1 (en) * | 2003-01-24 | 2004-10-14 | Immunomedics, Inc. | Anti-cancer anthracycline drug-antibody conjugates |
| US20050043215A1 (en) | 2003-02-19 | 2005-02-24 | Tamara Minko | Complex drug delivery composition and method for treating cancer |
| US8709998B2 (en) | 2003-04-22 | 2014-04-29 | Ipsen Pharma S.A.S. | Peptide vectors |
| AU2007221964B2 (en) * | 2003-04-22 | 2008-12-11 | Ipsen Pharma S.A.S. | Peptide vectors |
| US7097993B2 (en) | 2003-06-25 | 2006-08-29 | Wisconsin Alumni Research Foundation | Method for identifying an agent that modulates type 1 phosphatidylinositol phosphate kinase isoform β661 activity |
| WO2005086951A2 (en) * | 2004-03-10 | 2005-09-22 | Threshold Pharmaceuticals, Inc. | Hypoxia-activated anti-cancer agents |
| US20070060534A1 (en) * | 2005-06-30 | 2007-03-15 | Threshold Pharmaceuticals, Inc. | Anthracycline analogs |
| JP5340155B2 (ja) * | 2006-09-06 | 2013-11-13 | エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 細胞結合分子を有するジソラゾールのコンジュゲート及びそれらの誘導体、新規ジソラゾール誘導体、それらの製法ならびに使用 |
| EP1900742A1 (en) | 2006-09-07 | 2008-03-19 | AEterna Zentaris GmbH | Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof |
| WO2008100591A2 (en) * | 2007-02-14 | 2008-08-21 | The General Hospital Corporation | Modulation of nitric oxide signaling to normalize tumor vasculature |
| ES2547552T3 (es) | 2008-02-01 | 2015-10-07 | Genentech, Inc. | Metabolito de nemorrubicina y reactivos análogos, conjugados anticuerpo-fármaco y métodos |
| MX2010011079A (es) * | 2008-04-11 | 2012-06-01 | Tianjin Hemay Bio Tech Co Ltd | Derivados antibioticos de antraquinona tetraciclica con alta actividad, proceso para preparar los mismos y uso de estos. |
| CN101555264B (zh) * | 2008-04-11 | 2014-09-03 | 天津和美生物技术有限公司 | 具有高活性的四环蒽醌类抗生素的衍生物及其制备和应用 |
| WO2010009124A2 (en) * | 2008-07-15 | 2010-01-21 | Genentech, Inc. | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds |
| MX2011008774A (es) * | 2009-02-20 | 2011-10-24 | Ipsen Pharma Sas | Conjugados citotoxicos que tienen un compuesto de unión de receptores de neuropeptidos y. |
| CN102050856B (zh) * | 2009-11-03 | 2014-04-30 | 天津和美生物技术有限公司 | 具有高活性的表阿霉素的衍生物及其制备和应用 |
| ES2533710T3 (es) | 2010-12-02 | 2015-04-14 | Nerviano Medical Sciences S.R.L. | Proceso para la preparación de derivados de morfolinil antraciclina |
| CN105198966B (zh) * | 2014-06-26 | 2019-06-21 | 中国人民解放军军事医学科学院毒物药物研究所 | GnRH类似物-细胞毒分子缀合物、其制备方法及用途 |
| CN106573077B (zh) | 2014-06-30 | 2019-07-30 | 塔弗达治疗有限公司 | 靶向缀合物及其颗粒和制剂 |
| EP3045540A1 (en) | 2015-01-19 | 2016-07-20 | Æterna Zentaris GmbH | Enzymatic process for the regioselective manufacturing of N-Fmoc-doxorubicin-14-O-dicarboxylic acid mono esters |
| JP7057278B2 (ja) | 2015-10-28 | 2022-04-19 | ターベダ セラピューティクス インコーポレイテッド | Ｓｓｔｒ標的化コンジュゲート及び粒子並びにその製剤 |
| US10450340B2 (en) | 2017-02-16 | 2019-10-22 | Monopar Therapeutics Inc. | 3′-deamino-3′-(2″-pyrroline-1″-yl)-5-imino-13-deoxyanthracyclines and methods of preparation |
| US20210402016A1 (en) * | 2018-11-13 | 2021-12-30 | Provincial Health Services Authority | Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3725350A (en) * | 1972-04-26 | 1973-04-03 | Commercial Soluents Corp | Polymeric substances comprising the reaction product of melamine, aldehyde and oxazolidines |
| US4299822A (en) * | 1980-06-09 | 1981-11-10 | Sidney Farber Cancer Institute, Inc. | N-Trifluoroacetyladriamycin-14-O-hemiglutarate and -hemiadipate and therapeutic compositions containing same |
| US4464529A (en) * | 1982-07-20 | 1984-08-07 | Sri International | Analogues of morpholinyl daunorubicin and morpholinyl doxorubicin |
| FI102355B1 (fi) * | 1988-02-11 | 1998-11-30 | Bristol Myers Squibb Co | Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi |
| US5217955A (en) * | 1989-09-15 | 1993-06-08 | Biomeasure, Inc. | Treatment of cancer with peptide analog of bombesin, grp, litorin or neuromedin |
| US5304687A (en) * | 1989-12-19 | 1994-04-19 | Farmitalia Carlo Erba S.R.L. | Morpholinyl derivatives of doxorubicin and process for their preparation |
| ATE143023T1 (de) * | 1989-12-19 | 1996-10-15 | Pharmacia Spa | Chirale 1,5-diiodo-2-methoxy oder benzyloxy zwischenprodukte |
| DK0450480T3 (da) * | 1990-04-06 | 1995-08-14 | Univ Tulane | Somatostatinaloger |
| ATE127476T1 (de) * | 1990-04-06 | 1995-09-15 | Univ Tulane | Lhrh-analoge. |
| JP3169425B2 (ja) * | 1992-03-27 | 2001-05-28 | 三共株式会社 | アジドペンタンサイクリトール |
| US6214345B1 (en) * | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
-
1995
- 1995-11-27 US US08/562,652 patent/US5843903A/en not_active Expired - Lifetime
-
1996
- 1996-11-14 CN CNB961986050A patent/CN1137136C/zh not_active Expired - Lifetime
- 1996-11-14 AT AT96938216T patent/ATE251179T1/de active
- 1996-11-14 CZ CZ0135798A patent/CZ297297B6/cs not_active IP Right Cessation
- 1996-11-14 PL PL96326865A patent/PL187230B1/pl unknown
- 1996-11-14 WO PCT/EP1996/005029 patent/WO1997019954A1/en active IP Right Grant
- 1996-11-14 CN CNB021439192A patent/CN1166597C/zh not_active Expired - Lifetime
- 1996-11-14 EP EP96938216A patent/EP0863917B1/en not_active Expired - Lifetime
- 1996-11-14 AU AU75722/96A patent/AU709539B2/en not_active Expired
- 1996-11-14 UA UA98063318A patent/UA67722C2/uk unknown
- 1996-11-14 DE DE69630233T patent/DE69630233T2/de not_active Expired - Lifetime
- 1996-11-14 DK DK03010988T patent/DK1384710T3/da active
- 1996-11-14 DK DK96938216T patent/DK0863917T3/da active
- 1996-11-14 SK SK341-2004A patent/SK284672B6/sk not_active IP Right Cessation
- 1996-11-14 HU HU9903771A patent/HU229870B1/hu unknown
- 1996-11-14 CA CA002238574A patent/CA2238574C/en not_active Expired - Lifetime
- 1996-11-14 PT PT03010988T patent/PT1384710E/pt unknown
- 1996-11-14 DE DE69637604T patent/DE69637604D1/de not_active Expired - Lifetime
- 1996-11-14 NZ NZ322054A patent/NZ322054A/en not_active IP Right Cessation
- 1996-11-14 CA CA002471775A patent/CA2471775C/en not_active Expired - Lifetime
- 1996-11-14 KR KR10-2004-7004548A patent/KR100467899B1/ko active IP Right Grant
- 1996-11-14 PL PL358737A patent/PL191781B1/pl unknown
- 1996-11-14 KR KR10-1998-0703948A patent/KR100445754B1/ko active IP Right Grant
- 1996-11-14 BR BRPI9611647-1A patent/BR9611647B1/pt not_active IP Right Cessation
- 1996-11-14 ES ES96938216T patent/ES2205067T3/es not_active Expired - Lifetime
- 1996-11-14 PT PT96938216T patent/PT863917E/pt unknown
- 1996-11-14 EA EA199800492A patent/EA001372B1/ru not_active IP Right Cessation
- 1996-11-14 AT AT03010988T patent/ATE401305T1/de active
- 1996-11-14 ES ES03010988T patent/ES2310222T3/es not_active Expired - Lifetime
- 1996-11-14 SK SK628-98A patent/SK284392B6/sk unknown
- 1996-11-14 PL PL96358646A patent/PL188786B1/pl unknown
- 1996-11-14 JP JP52012397A patent/JP3987575B2/ja not_active Expired - Lifetime
- 1996-11-14 EP EP03010988A patent/EP1384710B1/en not_active Expired - Lifetime
- 1996-11-20 ZA ZA9609709A patent/ZA969709B/xx unknown
- 1996-11-26 IL IL11969196A patent/IL119691A/en not_active IP Right Cessation
- 1996-11-26 IL IL13468596A patent/IL134685A/en not_active IP Right Cessation
-
1998
- 1998-05-05 IS IS4734A patent/IS2178B/is unknown
- 1998-05-15 NO NO19982252A patent/NO324035B1/no not_active IP Right Cessation
- 1998-05-25 MX MX9804119A patent/MX9804119A/es unknown
- 1998-07-15 US US09/116,125 patent/US6184374B1/en not_active Expired - Lifetime
-
1999
- 1999-05-24 HK HK99102273A patent/HK1017363A1/xx not_active IP Right Cessation
-
2000
- 2000-02-23 IL IL13468500A patent/IL134685A0/xx unknown
-
2003
- 2003-07-09 HK HK03104934.8A patent/HK1052920B/zh not_active IP Right Cessation
-
2005
- 2005-03-01 NO NO20051111A patent/NO20051111L/no not_active Application Discontinuation
-
2006
- 2006-11-09 IS IS8567A patent/IS2634B/is unknown
- 2006-11-15 JP JP2006309698A patent/JP4778405B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX9804119A (es) | Analogos de antraciclina citotoxica dirigidos. | |
| GR3034312T3 (en) | Phosphonooxymethyl ethers of taxane derivatives. | |
| IL110660A0 (en) | Phosphonooxymethyl ethers of taxane derivatives | |
| HU9302762D0 (en) | N-sulfonyl-2-oxoindole derivatives being effective on vasopressin and/or oxitocin receptors | |
| IL159773A0 (en) | Taxol enhancer compounds | |
| IL103301A0 (en) | Pyrimidine nucleoside derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same | |
| IL107950A0 (en) | 7-Halo- and 7 beta, 8 beta-methano-taxols, antineoplastic use and pharmaceutical compositions containing them | |
| IL106672A0 (en) | 9-((substituted glycyl)amino))-6-demethyl-6-deoxytetracyclines | |
| AU3498397A (en) | Targeted drug delivery using sulfonamide derivatives | |
| RU95112841A (ru) | Полимерный конъюгат, способ его получения, производная 20-0-ациламинокамптотецина и способ ее получения, фармацевтическая композиция | |
| KR960701661A (ko) | AIDS치료용 약제학적 배합물중의 HIV프로테아제 억제제(HIV protease inhibitors in pharmaceutical combinations for the treament of AIDS) | |
| YU41199A (sh) | Hinoksalindioni | |
| KR950701646A (ko) | 폴리펩티드 봄베신 길항제(polypeptide bombestn antagonisis) | |
| CA2155018A1 (en) | C7 taxane derivatives and pharmaceutical compositions containing them | |
| DE3060186D1 (en) | Process for the solubilization of organic or mineral salts in organic solvents and complexes of organic or mineral salts | |
| CA2275451A1 (en) | Radioactive technetium and rhenium nitride heterocomplexes | |
| ZA941198B (en) | Highly concentrated TCF pharmaceutical preparations | |
| MY110974A (en) | Anthracycline conjugates, their preparation and their use as antitumor agents | |
| IL96160A0 (en) | Process for preparing(1r,2r)-2-(3-pyridyl)tetrahydrothiopyran-2-carbothioamide 1-oxides,the(1r,2r)-2-(3-pyridyl)tetrahydrothiopyran-2-carbothioamide 1-oxides thereby obtained and pharmaceutical compositions containing them | |
| GR862436B (en) | Method for preparing conjugate compounds of vinblastine and its derivatives and pharmaceutical compositions containing the conjucate compounds | |
| CA2022538A1 (fr) | Derives n-(vincristinoyl-23) et n-(noranhydro-5' vinblastinoyl-23) d'acide amino-1 methylphosphonique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| HU9500585D0 (en) | Hepatotropic conjugates of antiviral drugs, carriers thereof and pharmaceutical compositions containing them |